Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by